Searchable abstracts of presentations at key conferences in endocrinology

ea0038p235 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2015

Relationship between high-sensitivity C-reactive protein and anthropometric indices of obesity

Soyoye David , Kolawole Babatope , Ikem Rosemary , Enikuomehin Adenike

Background: Obesity contributes to the occurrence of many metabolic and cardiovascular complications including Type 2 diabetes, hypertension etc. Body adiposity is not just an energy store, but also an endocrine organ with elaboration of hormones and cytokines. Some of these cytokines have been implicated in the initiation and propagation of inflammation, and hence atherosclerosis.Aim: This study examined the relationship between high-sensitivity C-react...

ea0038p264 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2015

Influence of gender on the distribution of type 2 diabetic complications at the Obafemi Awolowo Teaching Hospital, Ile-Ife, Nigeria

Enikuomehin Adenike , Kolawole Babatope , Ikem Rosemary , Soyoye Bukunmi

Background: Gender specific differences appear particularly relevant in the overall management and outcome of type 2 diabetes mellitus (T2DM). We determined gender specific differences in cardio-metabolic risk, microvascular, and macrovascular complications in patients with T2DM.Method: Four hundred T2DM patients matched for age and disease duration were studied. Relevant clinical information, physical examination and laboratory data were analysed.<p...

ea0037ep1230 | Clinical Cases–Pituitary/Adrenal | ECE2015

Cushing's disease in a 7-year-boy due to corticotroph cell hyperplasia

Dineen Rosemary , McGurren Karen , Javadpour Mohsen , Costigan Colm , Agha Amar

Introduction: Cushing’s disease (CD) is very rare in children and is invariably caused by a corticotroph adenoma. However, corticotroph cell hyperplasia has only been convincingly shown in two previous cases of paediatric Cushing’s disease. We report the case of a 7-year-old boy with Cushing’s disease caused by coticotroph cell hyperplasia.Case report: Our patient presented with a 10-month history of obesity, hirsutism and growth retardati...

ea0037ep1337 | Clinical Cases–Thyroid/Other | ECE2015

Recurrent severe symptomatic hyponatraemia induced by low-dose oral cyclophosphamide in a patient with ANA-related vasculitis

Dineen Rosemary , Pazderska Agnieszka , Mullan Ronan , Gibney James , Sherlock Mark

Cyclophosphamide is an alkylating agent used in the treatment of malignant and autoimmune diseases. Severe hyponatraemia is a serious electrolyte disorder with life threatening neurological sequelae. We report a case of recurrent severe, symptomatic hyponatraemia that developed in a 61 year old female with systemic vasculitis and Sjogrens syndrome following low-dose cyclophosphamide.Case report: A 61 year old lady, with ANA positive systemic vasculitis p...

ea0033p28 | (1) | BSPED2013

Resurgence of Lipoatrophy as a complication of treatment with insulin

Anuar Azriyanti , London Rosemary , Edge Julie , Makaya Tafadzwa

Background: Lipoatrophy (LA) was commonly associated with insulin use prior to the development of purified insulin in the 1970’s, and then has virtually disappeared. In the last few years, however reports of LA among patients using analogue insulin preparations have increased. We report a case series of 4 patients from a tertiary paediatric diabetes unit presenting with LA while on treatment with analogue insulin via a continuous s.c. insulin infusion pump (CSII).<p c...

ea0031p135 | Clinical practice/governance and case reports | SFEBES2013

Multiple autoimmune diseases: is it rare?

Ojo Olubukola , Ikem Rosemary , Kolawole Babatope , Arogundade Fatiu

A 56 year old female who was referred to the Endocrine clinic with a history of progressive anterior neck swelling, weight gain, memory impairment and sluggishness. On examination she was found to be pale, had an anterior neck mass which moved with swallowing but not with tongue protrusion, is diffuse, firm non tender, measuring 8 × 6 cm. There was associated submandibular lymph node enlargement.Her thyroid function test revealed primary hypothyroid...

ea0031p231 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2013

Risk assessment of adult residents in ile-ife, South-Western Nigeria for type 2 diabetes mellitus

Ajani Gbadebo , Ikem Rosemary , Enikuomehin Adenike , Soyoye David , Kolawole Babatope

Background: Type 2 diabetes mellitus (T2DM) is a potentially preventable disease that is presently increasing in epidemic proportion worldwide. Its onset can also be delayed with an appropriate and timely intervention if people at risk are identified early. This study determined risk levels of adults in Nigeria for type 2 DM by using Finnish Diabetes Risk Score (FINDRISC).Method: During our local activities for world diabetes day in 2011, adults who were...

ea0031p237 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2013

Prevalence and associated risks for metabolic syndrome in nigerians with type 2 diabetes mellitus

Soyoye David , Adebayo Olorunfemi , Kolawole Babatope , Ikem Rosemary

Introduction: Diabetes mellitus is considered a cardiovascular risk equivalent. The presence of other cardiovascular risk factors in patients with diabetes may imply synergy for the occurrence and severity of cardiovascular morbidities and mortalities. Metabolic syndrome is the presence of these clusters of cardiovascular risks in an individual. Metabolic syndrome has been shown to be associated with some traditional risk factors and emerging risk factors.<p class="abstext...

ea0028p252 | Pituitary | SFEBES2012

Discordance between growth hormone and IGF1 in patients with acromegaly following recent guidelines

Scally Niamh , Swords Francesca , Gorick Sondra , Chipchase Alison , Temple Rosemary

Introduction: Discordance between growth hormone (GH) and insulin-like growth factor 1 (IGF1) is observed in up to 30% patients with acromegaly, with the most common finding being high IGF1 with normal GH levels. Recently published guidelines recommended a nadir GH of 0.4 μg/L rather than 1.0 during growth hormone suppression test as being indicative of controlled disease. This may lead to reduced discordance between GH and IGF1. Methods We measured nadir GH (Beckman Coul...

ea0028p256 | Pituitary | SFEBES2012

Pituitary regrowth following growth hormone replacement therapy.

Evans Nicholas , Saada Janak , Swords Francesca , Temple Rosemary

Introduction: Growth hormone (GH)-deficiency in adults is associated with a range of adverse outcomes that improve with GH replacement. Pituitary adenomas and their treatment account for a large proportion of patients with adult GH-deficiency. However, safety fears have arisen due to the mitogenic effect of excess GH on pre-malignant colonic polyp formation in individuals with acromegaly. This, along with anecdotal suggestions of pituitary tumour recurrence, has prompted furth...